News | June 05, 2015

Medtronic Announces CE Mark and European Launch of Euphora Semicompliant Coronary Balloon

Enhanced delivery system facilitates improved stent access to tight lesions

Medtronic, Euphora SC balloon, CE Mark, Europe, Richard Edwards

June 5, 2015 - Medtronic announced the launch of the Euphora semicompliant balloon dilatation catheter in countries that recognize the CE (Conformité Européene) mark in February. The first patient case with the Euphora was performed in the same month by Richard Edwards, M.D., consultant cardiologist at the Freeman Hospital in Newcastle, United Kingdom.

"After performing the first patient case with Euphora, it is the most deliverable balloon catheter I have used," said Edwards. "The exceptionally low crossing profile and pushability make it ideal for complex situations and workhorse lesions alike."

Pre-dilatation with a semicompliant balloon helps physicians determine lesion characteristics, stent selection and facilitates stent access to the lesions - a crucial step for patients with complex lesions.

The Euphora semicompliant balloon catheter features several design advancements including:

  • Delivery system with PowerTrac technology to provide superior deliverability (compared to major competitors) through tight lesions. The delivery system was first introduced with the Medtronic NC Euphora noncompliant balloon dilatation catheter last year and is also featured with the Medtronic Resolute Onyx drug-eluting stent; ­­­
  • Ultra-slim balloon material, a tapered proprietary inner shaft design and an optimized mini-wrap to reduce the wall thickness of the balloon and contribute to the extremely low crossing profile; 
  • Significantly improved insertion and retraction force to enhance navigation to lesion sites when using the Kissing Balloon Technique, a method for treating bifurcated lesions;
  • Environmentally friendly packaging, a reduced box size that has a smaller footprint on congested shelves and improved product labeling for fast readability to improve efficiency in the cath lab; and
  • Enhanced crossability may create economic value to the cath labs through the use of a single balloon prepping a lesion, thus reducing the need for the "step up" technique which requires several balloons of different size to first cross the tight lesions and then gradually expand sizing before treating with a stent.

The device launched in the United States in May.

For more information:

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Medtronic, IN.PACT Admiral DCB, drug-coated balloon, below-the-knee, European BTK IN.PACT clinical study, peripheral artery disease, PAD, launch
News | Peripheral Artery Disease (PAD)| March 09, 2017
Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-coated balloon (DCB...
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
Overlay Init